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CCL2 (MCP-1) MEDIATES CHRONIC PELVIC PAIN THROUGH MAST
CELLS IN EXPERIMENTAL AUTOIMMUNE CYSTITIS
FUAT BICER

ABSTRACT
Interstitial cystitis/painful bladder syndrome (IC/PBS) is a chronic
inflammatory bladder condition with unknown pathophysiology. Chronic pelvic pain
is one of the most important and disturbing symptoms of IC/PBS, beside urinary
frequency, urgency, and nocturia. Increased amounts of mast cells (MCs) and CCL2
have been found in bladder tissue and urine, respectively. Whether or not there is a
causal relationship between CCL2, MCs, and pelvic pain in IC/PBS is unknown.
Methods: Female BALB/c mice were immunized with a peptide consisting of
residues 65-84 of the bladder urothelium-specific protein uroplakin 3A to induce
experimental autoimmune cystitis (EAC), a model for human IC/PBS. Referred
visceral pelvic pain was measured using von Frey monofilaments at different times
after immunization. Lidocaine was instilled into the bladder, colon and uterus to
locate the source of the pelvic pain. CCL2 expression in tissues was measured by
qRT-PCR and ELISA, and MCs in the bladder were quantified by toluidine blue
staining. An MC stabilizer (cromolyn sodium), histamine H1 receptor blocker
(cetirizine), and histamine H2 receptor blocker (ranitidine) were administered orally
to show the relation of MCs with the pain. CCL2-/- and CCR2-/- mice, and CCR2
(CCL2 receptor) antagonist treatment were used to delineate the causative effect of
CCL2 on MC accumulation and chronic pelvic pain.

vi

Results: All mice immunized with the uroplakin 3A peptide developed pelvic
pain within 5 days and up to 40 days after immunization. Lidocaine alleviated the
pain only when it was installed into the bladder of EAC mice, confirming the bladder
origin of the pain. The amounts of CCL2 mRNA and protein, and the numbers of
MCs were markedly increased in bladder tissue up to 40 days after immunization with
peptide compared with controls. Administrations of cromolyn sodium and ranitidine
significantly decreased pelvic pain in the model. Moreover, immunization did not
establish chronic pelvic pain or accumulation of MCs in MCP-1-/- or CCR2-/- mice,
compared with wild type mice.
Conclusion: CCL2 has a vital role in causing chronic pelvic pain through
accumulation of MCs in this newly created EAC mouse model, and might be an
essential player in the pathogenesis of human IC/PBS.
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CHAPTER I
I.BACKGROUND AND SIGNIFICANCE
Interstitial Cystitis/Painful Bladder Syndrome (IC/PBS)
The International Continence Society (ICS) calls the disease as IC/PBS
(Interstitial Cystitis/Painful Bladder Syndrome). On the other hand, The European
Society calls it as IC/BPS (Interstitial Cystitis/bladder pain syndrome) [1]. IC/PBS is
a chronic inflammatory condition of the bladder characterized by symptoms of
urinary frequency, urgency and pelvic pain [2]. In IC/PBS, unlike other bladder
inflammations caused by infections, there is no bacterial infection and pathological
agent in bladder and urinary track [3]. Women are mainly affected by IC/PBS, but
men also suffer from it.
Definition
In the 1990, according to National Institute for Diabetes and Diseases of the
Kidney (NIDDK) Criteria (this criteria mostly used in research studies, not used for
clinic area) [4]; A diagnosis criterion for IC can be made when patients have bladder
pain

or

urinary

urgency

and

glomerulations

or

Hunner's

cystoscopy/hydrodistension and except criterions listed in a Table 1.

1

ulcer

during

Table 1: Except diagnostic criterions for Interstitial Cystitis
Awake cystometric capacity >350 mL using a fill rate of 30-100 mL/minute
Absence of intense urge to void at 100 mL gas or 150 mL liquid
Involuntary detrusor contractions on cystometry
Urinary frequency less than 8 voids per day
Absence of nocturia
Duration of symptoms less than 9 months
Cystitis (bacterial, chemical, post-irradiation), prostatitis, vulvitis (herpes) or vaginitis
Bladder, uterine, cervical, vaginal or urethral cancer
Bladder or lower urethral calculi
Age less than 18 years
Urethral diverticulum

The definition of IC has been widely varied over the past few decades. Before
2002, IC was defined as "An unpleasant sensation (pain, pressure, discomfort)
perceived to be related to the urinary bladder, associated with lower urinary tract
symptoms of more than six weeks duration, in the absence of infection or other
identifiable causes" according to the criteria of the National Institute for Diabetes and
Diseases of the Kidney (NIDDK), it is the so-called "NIDDK criteria"[4-6]. This
definition was too restrictive for general use. Therefore, in the 2002, IC/PBS was

2

defined, as “Painful bladder syndrome is the complaint of suprapubic pain related to
bladder filling, accompanied by other symptoms such as increased daytime and
nighttime frequency, in the absence of proven urinary infection or other obvious
pathology”. In 2006, the European Society for the Study of IC/BPS (ESSIC) defined
another system that also became reliable [7]. The presence of pain related to urinary
bladder and at least one other urinary symptom is used for the diagnosis of Bladder
Pain Syndrome (BPS), distinct from PBS. Other diseases that have similar symptoms
need to be excluded by cystoscopy with hydrodistension and biopsy (if needed). It
seems that there would be further definition during the coming years.
Prevalence
There are many variable diagnostic criteria for IC/PBS. Therefore, there have
been shown various prevalence rates in different studies. In the United States, it is
estimated that there are 1.2 million women and 82,000 men suffering from IC/PBS
and a total cost of IC/PBS patients in the US was nearly $65.9 million in 2000 [8, 9].
Between 1994 and 2000, annual national expenditures for interstitial cystitis are about
$37 million. However, annual costs for painful bladder syndrome significantly
enlarged from $481 million to $750 million[8]. Some other epidemiological studies
showed; there are reported incidence rates of 10 to 865 cases per 100.000 in term of
population-based studies [10, 11]; a survey from the United States Nurses' Health
Studies reported a prevalence of 52 to 67 cases per 100,000 women[12].
A diagnostic survey from out of the United State of America done by
urologists showed that 2.8 percent of patients examined during in first two week
period were diagnosed with IC (7.9 % female/0.4% male,≈8: 1) [13]. Another group
reported a prevalence of 197 cases per 100,000 women and 41 per 100,000 men in a
primary care population[14]. However, the same population has much higher
3

prevalence of IC/PBS symptoms such as 11 percent of women and 5 percent of
men[15].
Some investigators say that if women have chronic pelvic pain, they may
actually have high incidence of IC as well as men who have lower urinary tract
infection or prostatitis may mostly have IC [16-18].
Epidemiology
IC/PBS was mostly diagnosed in women according to many studies [4], the
ratio of disease in female and male population is reported as 4.5 to 9 females to one
male [10, 13, 19]. Most patients are probably diagnosed about age of 42 to 45 years.
Sometimes physician diagnosed them even in childhood terms [11, 20, 21].
Monozygotic twin is more prone to IC than dizygotic twin pairs. That shows there can
be a genetic susceptibility to IC[22].
In a population-based study, the women who have history of lower urinary
tract infection, depression, some cardiac and thyroid related medication usage, and
hysterectomy are more prone to have IC/PBS [23]. Men who have depression are
more prone to IC/PBS[23].
Etiology and Pathogenesis
The etiology and pathogenesis of IC/PBS is still obscure, although several
theories have been described. One of the most popular hypotheses was developed due
to the urothelium damage caused by inflammatory or autoimmune conditions;
therefore the bladder is permeable to anything in the urine [24, 25]. An alternative
theory suggests that initial urinary infections start and causes a series of reactions in
the bladder such as nerve stimulation. This stimulation triggers an inflammatory
response, or neurogenic inflammation. After that, release of substances such as MCP-
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1 may cause the secretion of mast cell mediators, histamine and leukotrienes resulting
in inflammation and tissue damage [25, 26].
In addition, the other etiologic theories are respectively activation of bladder
mast cells, neuropathic changes, neurogenic inflammation, some toxic substances in
the urine flow, and unknown infection [27].
On the other hand, many studies showed that IC patients have urothelial
abnormalities in bladder biopsies. However, It is unknown those abnormalities is
primary phenomena or secondary phenomena. Those abnormalities can be: different
expression level of HLA class I and II antigens in urothelium, changes of
glycosaminoglycan (GAG) layer, the transition of urothelium cell to squamous cell,
and low level of uroplakin expression and chondroitin sulfate [28-33]. In IC patients,
NFkB gene activation is increased, and interleukin-6 and P2X3 ATP receptor are
more expressed compared the control group. Some patients have abnormality in
Tamm-Horsfall Protein (THP) [34].
The glycosaminoglycan layer that protects the surface from irritants in urine
normally covers the urothelial surface of bladder. When GAG layer is damaged, the
irritants penetrate into urothelium and affect inside nerve and muscle tissues [35].
Therefore, further tissue damage, pain, and hypersensitivity are inevitable. In addition
to that, mast cell also propagates those damages [36, 37].
One study reported that Antiproliferative factor (APF) may also have a
pathogenetic role in the generation of IC symptoms. The urothelium of IC patients
express APF as known a lipoglycopeptide [38, 39]. APF can play a role in urothelial
activity in terms of growth and function [40].
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Neurologic changes in bladder accompanied to central sensitization and
increased activation of bladder sensory neurons have an effect on the generation and
maintenance of IC symptoms during the normal periods [41, 42]. This increased
sensitivity may be due to bladder abnormalities or central nervous issues. New
pathways can be involved or there can be increased activity of the central nervous
system. Some animal models showed other diseases (placed in pelvic area) that cause
hypersensitivity may have a role in IC patients [43, 44]. Those findings guide us
bladder afferents can overlap with other afferents comes from somatic parts [45, 46].
Recent studies have shown that there are autoantibodies, which recognize
urothelium cells as targets in the urea and serum of IC patients [47, 48]. In addition,
according to the many studies, activated mast cells (MCs) have an important role in
the formation of IC/PBS [49-51]. Detrusor MC density, sub-mucosal MC density, and
the MC found in the mucosa were increased during IC/PBS in bladder [52-54]. In
most cases of IC/PBS, it was observed that activated MC numbers increase as much
as 10 fold in bladder[49]. In our recent study, our colleagues showed autoimmunity
against the bladder epithelium in a mice study. Our laboratory immunized mice with
peptide derived from bladder specific protein-Uroplakin 3A (Uroplakin 3A 65-84
peptide). After this immunization, the created this outstanding model characterized in
term of both immunologic and urodynamic phenotype. These mice have increased
levels of antibodies against this peptide. In this model, it has been shown that there is
a CD4+ T cell mediated Th1 response. This mouse model mainly mimics the human
IC/PBS disease and significantly increased the pelvic pain response on suprapubic
area were demonstrated [55].
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Clinical Findings
The clinical presentation of IC/PBS is common and variable [56, 57]. Pain is
associated with all patients with PBS/IC. The pain is related to bladder filling and/or
emptying, and usually accompanied by urinary frequency, urgency, and nocturia. The
pain is normally placed suprapubic area originated from bladder, but sometimes it
patters as unilateral lower abdominal area or low back area [58-61]. The severity of
pain was changing due to bladder filling situation from mild to severe pain. Most
patients fell well when the bladder is voiding. This clinical features gives physicians
clue to think IC/PBS disease [62]. Some patients could have other kind of diseases at
the same time that has also pain symptom such as irritable bowel syndromes, uterine
related diseases, vulval problems and fibromyalgia [63, 64].
The exacerbation of IC/PBS changes term to term and can be affected by diets
(coffee, alcohols, and some fruits) or the present condition that patients are in such as
exercises [1, 65, 66].
The miserable symptoms such as pain and frequent voiding make patients very
uncomfortable during working, and sexual relation. Having voiding many times in a
day affects on the comfort of life style that ruins the life. Sometimes, patients can stay
on the toilet for hours. In surveys, 50 percent of patients are unable to work full-time,
75 percent of patients have dyspareunia, 70 percent of them have reported sleep
disturbance [67, 68]. One of the most important problems in IC/PBS patients are
sexual dysfunction such as lack of interest (31%), arousal difficulties (19%), inability
to achieve orgasm (25%), performance anxiety (12%), pain (15%), and lack of
pleasure (23%) [68-70].
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Diagnostic Evaluation
The guideline was published about IC/PBS by the American Urologic
Association (AUA) [71] and European Association of Urology (EUA) [72]. The
diagnosis of IC/PBS based on the presence of characteristic symptoms in both
genders. Other disease such as urogenital cancers, urinary tract stones and infection,
and irritable bowel syndrome should be excluded carefully by desired applications.
Those applications;
1-

Physical examination [71]: It is very vital method to diagnose IC/PBS

or to exclude other problems, which is not IC/PBS. Even with small observation of
patients would give physician clues to diagnose. Physician can evaluate bladder and
any other around organs through abdominal wall to look at their present conditions. In
case of bladders problems, the physician can feel the tenderness of pelvic organs due
to sensitization of afferent nerve fibers in the dermomyotomes to which the bladder
refers. In addition, vaginal speculum and bimanual examination can be used to
examine the region, but sometimes it can be difficult to use this method due to
tenderness. Ultrasonography is other a useful technique to evaluate the area.
Sometimes physical examination cannot be enough to diagnose due to allodynia that
can be source from other organs. In this case, empiric treatment would be applied. If
the symptom were still continuing even with empiric medication, the diagnosis would
be reevaluated.
2-

Laboratory tests: Urine is the most essential sample to be used in

laboratory procedures such as checking infection and hematuria by microscopy,
culture, and some basic techniques. Urine cytology and cystoscopy are also need to be
performed in some patients. A post-void residual urine volume can be measured
manually. In mice studies, the laboratory tests that have been used for IC/PBS
8

evaluation are ELISA, western blot, RT-PCR, Immuno-staining methods, Frequency
voiding chart (FVC) and so on[73].
3-

Hydrodistension: Bladder is filled with water until 70 cm pressure is

reached. During the procedure, bladder is examined in term of characteristic findings
of IC such as Hunner’s ulser and glomerulations. However, it is not e requirement
technique for diagnosis of IC/PBS[74, 75].
4-

Bladder biopsy: Urologists can use bladder biopsy to distinguish

other disorders from IC/PBS. It is not required for a diagnosis of PBS/IC. Bladder
biopsy has been done to 204 patients with clinical diagnosis of IC [76]. It has been
shown that only 50 percent of patients have an increase in mast cell in the bladder
lamina propria, 11 percent of then has damage of urothelium (ie, an ulcer), 14 percent
has granulation tissue in lamina propria, and vascular density and submucosal
hemorrhage occur in 67 percent [77].
5-

Potassium sensitivity test: Some researcher used the potassium

sensitivity test (PST) for diagnosis of PBS/IC[78], but is not suggested for routine use
for PBS/IC [79]. During this test, he bladder is filled with potassium chloride and then
occurring pain would be an indicative bladder hypersensitivity and suggestive of
PBS/IC.
6-

Biomarkers: There have been markers being proposed for diagnosis

of IC/PBS. One of them was anti proliferative factor (APF) that is a promising
marker. One study showed that the sensitivity and specificity of APF is very high in
IC patients versus control groups. However, this marker need to be further
investigated before recommendation for being a diagnostic marker[38].

9

Treatment of Painful Bladder Syndrome/Interstitial Cystitis

There is still no any promising treatment for IC/PBS because of many reasons
such as unknown clear etiology, pathophysiology, and most importantly unqualified
designed clinical trials for treatment [56, 80]. There are many treatment diversities of
IC patients due to lack of understanding the treatment of the syndrome. In those trials,
physicians treated 581 IC patients with 183 different type of therapy. That is why,
treatment of IC is still a big problem in clinicians [81]. Most patients get empiric
therapy rather than actual therapy [27].
According to the American Urologic Association, the ideal treatment approach
to IC/PBS patients from at the beginning of disorder should be the least invasive and
toxic treatments and later more invasive unless there is no effective response [71].
Therapies are explained below;
A- Nonspecific Therapies
There are many nonspecific ways have been used for IC/PBS patients such as
psychosocial therapy, referring pain management specialties, avoiding activities
associated with flares, and behavioral therapy.
1- Psychosocial support
It is very common method that has been using in chronic pain disorders [82,
83]. There are two groups such as the Interstitial Cystitis Society and the Interstitial
Cystitis Network to help patients to overcome their uncomfortable situation. Those
types of centers can refer to a psychologist for counseling of the disease. Depression
related chronic pelvic pain should be referred to a professional health specialty.
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2- Referral to pain management specialists
In any case of unresponsive of pain should be evaluated by pain management
specialty. Referral to specialists in pain management should be considered if the full
range of pain management options is not available within the practice.
3- To treat flares that aroused from activities of IC/PBS patients
Some human activities can cause trouble situation such as sexual activities,
recreational activities when the person has IC/PBS disorder [68, 84-86]. In addition,
some food mentioned previously may cause uncomfortable feeling. To avoid from
those activities and a certain foods consuming can help patients to live more
comfortable and relief [27, 87-89].
4- Behavioral therapy
Sometimes, educating the patients help many diseases in term of therapy. For
example, IC/PBS patients can have diminished functional bladder capacity. Those
patients can be educated to be expanded function of bladder [90, 91]. For instance,
the voiding interval first week can be 30 min, second week 1 hour, and it can keep
being longer and longer. Only one study has shown that the timed voiding in IC
patients reported 15 of 21 patients experienced a 50 percent decrease in their IC
symptoms [92].
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B- Specific Therapies
1-Pentosan polysulfate sodium (PPS)
PPS is the only oral medication approved by the United States Food and Drug
Administration (FDA) for treatment of IC [93]. PPS is a kind of protein that may be
rebuilt the damaged of glycosaminoglycan [94]. PPS is more effective than placebo
for treatment of IC that shown in one study [95].
2-Intravesical heparin and lidocaine
Some investigators showed those therapies have improvement effect on
IC/PBS [96-98]. For example, one of them is showed that 65 % percent of 23 IC
patients were improved on the Patient Objective Rating of Improvement of Symptom
scale [98].
3-Intravesical-dimethyl sulfoxide (DMSO)
FDA also approved DMSO for use in IC in 1997 [93, 99]. It may have some
nonspecific effects such as antiinflammatory, analgesic, smooth muscle relaxing, and
mast cell inhibiting effects [100, 101].
4-Intravesical-botulinum toxin
FDA is not approved botulinum toxin for the treatment of IC. This therapy is
based on the ability of botulinum toxin to modulate sensory neurotransmission. Some
researchers showed the benefit of botulinuim toxin on IC/PBS [102, 103].
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C- Neuromodulating therapies
IC/PBS is a kind of disorder that has more neurological involvements. That is
why, there are been many treatments have been proposed for use in IC/PBS treatment
that is related with Neuronal issues. These include:
1- Amitriptyline
This tricyclic antidepressant is used in many problems such as post-herpetic
neuralgia, diabetic peripheral neuropathy, and chronic low back and pelvic pain [104109]. Dr. Hanno et al. used amitriptyline using for IC/PBS resulted in a significant
decrease in daytime frequency and pain [110]. However there are many side effects of
amitriptyline include anticholinergic effects, sedation, weight gain, orthostatic
hypotension, and conduction abnormalities [111].
2- Gabapentin
Gabapentin is an antiepileptic agent that can be used treatment of painful
disorders [112]. Some studies showed that a group of patients that have urogenital
pain get benefit from the treatment of gabapentin [112, 113]. There is also an animal
study that showed the effectiveness of gapapentin on pain related from pelvic area
[114].
D- Electrical stimulation therapy
This FDA approved method used in some patients for the treatment of urinary
and urgency. The results were effective; however, FDA approval is not specifically
for treatment of PBS/IC. This device placed on S3 sacral nerve root and attached to
the special designed power [115]. Some studies proposed that this technique improves
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the dysfunctional voiding and pelvic pain in patients with interstitial cystitis [116118].
E- Physical therapy
Some patients get benefits from physical therapy such as myofascial physical
therapy, manual physical therapy, and pelvic floor massage [119-121].
F- Mast cell related therapies
Mast cell has a critical role in the development and maintenance of IC/PBS
symptoms in both human and in animal models [122, 123]. Some direct and indirect
mast cell function related drugs were used for treatment of IC such as H2 receptor
blocker, and montelukast. The treatment with cimetidine, H2-receptor blocker, has
benefits on IC, but it is not commonly used [124-126]. Montelukast treatment showed
an improvement of frequency and pain of interstitial cystitis [127, 128].
G- Immunomodulatory treatments
Some immunomodulators has an effect on the treatment of IC/PBS patients
such as cyclosporine A, bacillus Calmette-Guerin (BCG) [129-133].
H- Surgery
Sometimes, urologists cannot find a solution to the pain originated from pelvic
area. At this point, the surgical procedure needs to be applied in same case [134].
It seems that the therapy for IC has been in wide range due to many reasons
such as unknown pathopyhsiology, not easy diagnosable disease, very common
symptoms with other disease, not so much research has been done so far.
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MAST CELLS
Development, identification, and physiologic roles
Dr. Ehrlich et all firstly described the mast cells “Mastzellen” in 1879 when he
was in medical school [135]. Mast cells are placed in almost all tissues of body. Most
of them are positioned in main entrance of body such as urogenital system,
gastrointestinal system, and respiratory system and in dermal and articulation tissues
[136-142]. They are also seen in heart and vertebras [143-145].
It is been long time Mast cells have been acknowledged for the involvement in
many diseases that involve asthma, rhinitis, atopic dermatitis, anaphylaxis, urticaria,
and conjunctivitis. They also play a role in regeneration and protection of body [145147].
Anatomic Locations of Mast Cell
In normal tissues, Mast cells mostly place in connective tissues of organs and
vascularized organs. Mast cells play an important role in communication of external
and internal environment in terms of foreign organisms and antigens recognition
[148-150]. The places Mast cells reside are the dermis, intestinal mucosa and
submucosa, conjunctiva, and respiratual mucosa [136, 151-154]. One study showed
that Mast cells accumulate in dermal tissue within communication of blood vessels,
nerves, and lymphatics. There has been shown huge number of accumulation of Mast
cells per mm3 of skin [154, 155]. Mast cells may be having effect on vascular
structure, blood supply with their released mediators within those locations [156].
Mast cell also found in central nervous system [157].
Amount of mast cells are increased in a plenty of inflammatory diseases such
as rheumatoid arthritis, psoriasis, asthma, pulmonary fibrosis, inflammatory bowel
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diseases, and cardiovascular diseases. However, their roles still not clear [141, 158162]. Another famous disease, Mastocytosis is also kind of skin disease that has huge
accumulation of Mast cells [163].
Collection and Culture of Mast cell
Mast cells are very hard to work in vitro [164]. MC are the multifunctional
immune cell source from multi-potent hematopoietic progenitor in the bone marrow,
which are produced as undifferentiated MC and they become mature and acquire their
characteristics in the tissues they are sent [165-169]. Mast cells can be study in vitro
condition by getting with different techniques.

Those ways can be from bone

marrow, solid tissues, human cord blood, and peripheral blood [170-174]. When they
are used for in vitro experiments, those types of mast cell collection can have some
problems such as different functionality, abnormality and natural visibility rather than
natural tissue mast cell [175, 176]. For example, sometimes for mast cell culturing,
co-culture of fibroblast and mast cell help to get similar mast cell condition to natural
mast cell [176].It is also very hard to isolate from tissues [177]. Other problem is that
murine mast cell can be different than human mast cell in terms of phenotype and
distribution.
Because of the difficulties in collecting human mast cells, mast cells from
mice are often utilized instead. However, the distribution and phenotype of murine
mast cells are substantively different from that of human cells [164].
Development of Mast cell
Mast cells originate from pluripotential CD34+ stem cells that are inherent in
the bone marrow and spleen [178-180]. Myeloid pathway is common in almost
hematopoietic cells, and sharing similar mediators with monocyte/macrophages and
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granulocytes. Mast cells leave the hematopoietic tissues as committed progenitors
[178, 181, 182].
SCF (stem cell factor=kit ligand) and IL 4 have very important role in mast
cell development and activation [183-185]. SCF that binds to the c-Kit receptor
(CD117) works as an important growth factor in hematopoiesis, spermatogenesis, and
melanogenesis [186]. The receptor tyrosine kinase c-kit, receptor for SCF, expressed
by most hematopoetic cell continues along with myeloid differatation. It is used an
early marker for mast cell precursor. Mast cells continue express this marker during
its whole life rather than basophils [137, 181, 187].
Migration into tissues
This process can be depend upon the interaction of endothelial cells and mast
cells initially, and then, many tissue sourced mediators such as adhesion molecules,
chemokines, cytokines, integrins and immunoglobulin and receptors have been
proposed play a role in mast cell regulation [188-191]. As an example, stromal cellderived factor-1 (SDF-1) may be regulate mast cell migration and mediator
production [192]. Other example, IL 3 dependent murine bone marrow-derived mast
cells (BMMCs) may be more adhesive and proliferative in tissues when they come
across with the matrix protein, and vitronectin [193].
It seems every organs can has their own mast cell progenitors based on limited
studies [179, 194]. When they migrate the tissue, they can undergo differentiation by
hosting tissue [195]. For instance, MCp expression of the integrin alpha4beta7 (a4b7)
can help mast cell progenitors migrates into the tissue in an animal study. The integrin
alpha4beta7 is doing this movement by binding to mucosal addressing cell adhesion
molecule-1 (MadCAM-1) and vascular cell adhesion molecule-1 (VCAM-1) present
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on vascular endothelium expressed in Peyer's patches and lamina propria. IL-8
receptor on both mast cell progenitors and the vascular endothelium causes specific
migration of the cell into intestinal mucosa [196, 197].
In a mouse lung study, they showed that mast cell accumulation in submucosa
is less during absence of inflammation. However, during allergic inflammation, mast
cell progenitors significantly increased about >25 fold in the mouse lung tissue by
interaction of a4b1 and a4b7 integrins on the MCps and VCAM-1 and CXCR2 on the
endothelium [198, 199].
Chemoattractants
Mast cell may migrates to tissues under a variety of chemokine, cytokine, and
growth factors such as SCF, MCP-1, and MIP-1 alpha and IL-3. The C-C
chemokines, RANTES (Regulated on Activation Normal T-cell Expressed and
Secreted) and monocyte chemotactic protein (MCP-1) has a role in migration of
human cultural mast cell and mouse bone marrow-derived mast cells on vitronectin
and laminin [200-204].
Phenotypes of mature mast cell
Mast cell related sophisticated studies have been done on animal mouse
models. There are described a few mature mast cell subtypes in terms of their
location, granule contents, mediators production and behaviors [137, 205]. Two
subtypes were described in the mouse: murine mucosal mast cells and murine
connective tissue mast cells, the difference are their secretions and their environments
changes [206-208]. Another study showed that mucosal mast cells secrete both
prostanoides and cysteinyl leukotrienes, connective tissue mast cells mainly secrete
prostanoids [209].
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In the same way, mast cell types in human studies have been categorized
based on their secretion from the granules of mast cell. One of them is the one that has
more tryptase is called MC-T (mostly located in mucosa), other one is containing
trptase, chymase, and carboxypeptidase A is called MC-TC (mostly located in
submucosa and connective tissues) [209, 210].
Thus, the MC-T and MC-TC are comparable to mMMC and mCTMC,
although due to the plasticity of this cell and differences in the proteases between the
two species, this is an oversimplification and caution is advised in drawing too strong
an analogy between the murine and human systems.
1-Mucosal mast cells
They are mostly placed in mucosa of intestinal and respiratory epithelial cells,
which involved in inflammation associated with Th2 responses. Allergic diseases
specifically related with respiratory system and intestinal inflammations increases the
numbers of mucosal mast cells [211-213]. The differentiation of mast cell depends on
micro-environmental changes of tissues that mast cell located[206].

2-Connective tissue mast cells
Connective tissue mast cells are located in submucosal areas that have a
variety of connective tissues[214]. Those type of cell is dependent to Th1 cell
response [214].
Another study classification for MCs is shown. There are two type of MC is
described according to their granules and degranulation of them in cytoplasm. One of
them is called activated MCs show degranulation and release of toluidine blue–
positive remnants. Other one is resting MCs show intense granule store in cytoplasm.
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There is more intracellular and intravesicular accumulation of toluidine blue in resting
MCs [215].
As mentioned previously, mast cell significantly increases in some diseases
such as asthma, parasitic infections, rheumatoid arthritis, scleroderma, mastocytosis,
atopic rhinitis, atopic eczema, dermatitis, psoriasis, acute allergic reactions, urticarial
diseases, conjunctivitis, neoplastic diseases chronic renal and lever diseases, and
intestinal inflammatory diseases [216-218].
Cellular Identification of Mast cell
Mast cells are mostly round mononuclear cells, which have many types of
cytoplasmic morphology. There is two type of mast cell in terms of secretion
condition such as activated mast cell that has no or a few granules in the cytoplasm
and resting mast cell that has a lot of granules in cytoplasm while staining with
toluidine blue (Figure 5). Cell diameter ranges from 8 micron to 20 [219, 220].
Staining properties of Mast cell
The mast cell has various metachromatic cytoplasmic granules that almost
occupy 50-55% of the cytoplasm [221, 222]. The surface of mast cell is scanned by
electron microscopy that show mast cell has numerous short and long microvilli and
bulges on its surface, which is has connection with inside granules [222].

The

diameter of those granules is about 0.5-0.7 µm [222]. Mast cell is stained to redpurple with the basic dye toluidine blue. The color is due to granule contents that has
highly sulfated, anionic proteoglycans [223].
Some investigators worked with electron microscopy showed that there are
two different structure of mast cell described. One of them is the scroll-like structure
related with mucosal mast cell, which represents tryptase phenotype. Other one is a
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lattice-like granting pattern related with submucosal mast cell, which represents
tryptase/chymase phenotype [224-226].
Physiologic Roles of Mast cell
Mast cells have roles in both physiologic and pathogenic processes. Mast cells
play very important role in defense mechanism against bacteria, parasites, and viruses
[227-234]. Mast cell is important in both innate and adoptive immunity [228, 233,
235]. Specifically, mast cells recognize pathogenic organism from their surface
receptor, after that MCs call and induce leukocytes and other cell that involve in
defense mechanism. In this process, mast cell is a key cell against pathogens and
tissue repair [228, 230].
Mast cell plays very important essential role in innate immunity [228]. Mast
cells are defending host body against pathogens by releasing some products such as
chemokine, cytokines, lipopolysaccharide, and peptidoglycan [228]. In addition to
that, toll-like receptor (TLR) on mast cell is also significant in terms of activation of
mast cell [233, 236, 237]. Mast cell can work as a phagocytosis cell that involve in
Salmonella typhi and Escherichia coli [238]. Mast cell can produce cathelicidins that
causes bacterial cell (such as streptococci), and tumor cell lysis [239, 240]. A mast
cell-deficient mice are more susceptible to toxin such as snake and honeybee venoms
[241].
Mast cell-derived cytokines are very important in terms of hematopoetic cell
recruitment into infection area [242, 243]. Specifically, mast cell derived tumor
necrosis factor (TNF) plays a role in recruitment of dendritic cells [243].
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Mast cell in Acquired immunity
Mast cells play very important role against parasitic infections, even though its
mechanisms is not fully understood [244-246]. IgE is an important antibody against
intestinal parasitic infestation [244]. Mast cell plays roles in both Th1 and Th2
response [214, 247].
Mast cells have been implicated in various physiologic and regenerative
processes including; some intestinal, respiratory functions that have protective effect
against invaders pathogens. They also consider response reactions against allergic
diseases [230, 248]. Mast cell is effective in wound healing and scar formation by
stimulating fibroblast proliferation and collagen synthesis that also limits infections
[249, 250].
Mast cells in allergy causes two step reaction that categorized early phase
response and delayed phase response. Early phase response, which happens within
10 minutes, is due to histamine release from mast cell that causes skin lesions such as
edema, itchiness symptoms that represent in allergic disease [142, 251]. After early
phase, late phase response will start in some patient that is characterized with
cutaneous erythema, warmth, and induration. This phase takes longer than early phase
about 6 – 8 hours, which is more related with other cell accumulation such as
mononuclear cells, eosinophils, and neutrophils [251, 252].
Mast cell derived mediators

As I mentioned previously, mast cells release a variety of mediators that can
be divided into three overlapping categories such as preformed mediators, newly
synthesized lipid mediators, and cytokines and chemokines.
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A- Preformed Mediators

Those mediators are histamine, neutral proteases, proteoglycans, and some
cytokines, such as TNF-alpha (TNF-α), which is released into environment upon cell
stimulation. Those mediators are secreted rapidly and mediate same allergic reactions
such as edema, bronchoconstriction, and increased vascular permeability.

1-Histamine is one of the most important neurotransmitter that is secreted
from mast cell [253-256].

The mean level of histamine in human cutaneous mast

cells are measured as showed 1.9±0.8 µg 106 cells [256]. Histamine involves in both
local immune response and physiological function in organs [253, 257]. It also plays a
role in pain IC/PBS patients. High levels of histamine metabolites are detected in IC
patients [77, 258, 259]. Histamine shows it effect through several receptors; H1, H2,
H3, and H4 located on target cells [260, 261].

H1 receptor distributes in organs that involve smooth muscle, endothelial
cells, adrenal medulla, heart, CNS [260]. H1 receptor stimulation cause many type of
reactions such as systemic vasodilatation, bronchial and intestinal smooth muscle
contraction, modulate circadian cycle, flushing, itching hematopoietic cell
chemotaxis, and pain regulations [230, 262, 263]. As an example, H1 receptor
knockout mice showed less pain perception versus control group [263] and reduce
lung inflammation by decreasing t cell migration [262].

H2 receptor distributes in organs that involve Gastric parietal cells, vascular
smooth muscle, suppressor T cells, neutrophils, CNS, heart, uterus. The effects that
occurred by inducing H2 receptor are gastric acid secretion, smooth muscle
relaxation,

increased

vascular

permeability,
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airway

mucus

production,

hyperpolarization or facilitation of signal transduction in CNS, block of Ca2+dependent potassium conductance, and inhibition of lymphocyte function [260, 264].

H3 receptor is located on CNS, peripheral nerves, endothelium, and
enterochromaffin cells. The functions induced by H3 receptor stimulation are gastric
acid inhibition in dog, inhibition of neurotransmitter release, relaxation of middle
cerebral artery of rabbit, increase current of Ca dependent channel in smooth muscle,
and inhibition of neuronal stimulation [260, 265].

H4 receptor is highly expressed in bone marrow, CNS and white blood cells
and regulates neutrophil release from bone marrow [266, 267]. Histamine H4 receptor
has a role in chemotaxis and calcium mobilization of mast cell [261]. H4 -/- mice
showed less infiltration of eosinophils and lymphocytes [268].

In general, Histamine increased mast cell density and has effect on mast cell
degranulation, also induce neuronal density and depolarize neuronal cells [269-272].
Histamine also mediates pelvic pain [273]. Histamine receptors are expressed on
neuron and mast cell [274-276].

2- Serotonin release was showed in some term life of human being such as
during fetal development and in some adult life condition [277, 278].

3- Proteoglycans are heparin and chondroitin sulfate that cause mast cell
stained as metachromatic. These are composed of a peptide core, serglycin,
complexed to glycosaminoglycans[279, 280].

4-Tryptases and other proteases such as chymases, cathepsin G, renin, and
carboxypeptidase A are important other products released by mast cell [281, 282].
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Tryptases are the one which produces much more than other proteases [283, 284].
Some of them are related with pain. As an example, tryptase causes hyperexcitability
of guinea-pig submucosal neurons [285]. Chymase can indirectly induce pain by
recruit neutrophils, eosinophils and other inflammatory cells [286].

B- Newly Synthesized Lipid Mediators and NGF

Mast cells can synthesis eicosanoids derived from arachidonic acid such as
prostaglandins (PG), leukotrienes (LT), and growth factor as NGF and plateletactivating factor (PAF) [287-289]. Those mediators releases 15 minutes to one hour
after the cell activation. They are mostly involved in allergic symptoms [290, 291].

1-Prostaglandins

Mast cells mainly produce prostaglandin D2 (PGD2) that involve in
respiratory problems such as asthma [292, 293]. As an example, PGD2 receptor
deficient mice decreases airway reactivity in asthmatic mouse model [294].

2- Cysteinyl leukotrienes

Activated human mast cells can release the cysteinyl leukotrienes, LTC4, and
lesser amounts of LTB4 [295]. The cysteinyl leukotrienes play a role in microvascular
permeability and are also responsible for wheal and flare responses in diseases [295].
Most of them play a role in allergic diseases such as asthma, IC/PBS, irritable bowel
disease and rhinitis [296-298].
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3- Platelet activating factor

Mouse and human mast cell can produce platelet activating factor (PAF) [299,
300]. PAF has a chemotactic role in some hematopoetic cells [301, 302]. PAF one of
the important factor involve in pain such as induced pain hypersensitivity and role in
pain signaling [303].

4-NGF
There are many study showed that NGF significantly involve in IC /PBS pain
and other pain related disease. NGF is very important for sympathetic and sensory
neurons’ maintenance and survival [304]. NGF increases in IC, it stimulates mast cell.
And then mast cells secrete cytokines that play role in neuronal sensitization and
pelvic pain. NGF is also directly secreted by Mast cell [305]. Dr. Lewin et al showed
NGF has important role effect on A- delta and C fibers in term of pain [306]. NGF is
also a trigger on both neural excitability and neural density in peripheral tissues [307].
NGF play a role in VEGF production that induce angiogenesis, and then neuronal
tissues density [307].
C- Cytokines and Chemokines

Mast cell can produce many cytokines and chemokines that involve in other
inflammatory cell migration [289, 308]. Those cytokines are IL-4, IL-5, TGF-beta
(transforming growth factor), and TNF-alpha (Tumor necrosis factor-alpha) [161,
308-311]. Mast cell secreted chemokines mostly belong to the CC chemokines
(macrophage chemotactic protein-1 =MCP-1 or CCL2) and the CXC chemokines (IL8) families [308, 312-314]. IL-1b, IL-3, and platelet derived growth factor (PDGF)
can be produced by mast cell [315, 316].
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Mast cell play pivotal role in IC/PBS and pain related hyperalgesia and
neurogenic inflammatory diseases by their products [317-320]. As an example, MC
can produce adenosine phosphates, bradykinin, histamine, leukotrienes, potassium,
lymphokines, tumor necrosis factor (TNF), and prostaglandins in IC, those products
can cause many symptoms observed in IC. Most common one is pain [321]. Other
example, Histamine, PGD2 and proteases are important mediator for pain [146]. It
seems that MCs has a crucial role in pain, which highlights need for further
investigation.
Chronic pelvic pain
Pain is a feeling of unpleasant sensation resulting of many types of diseases. In
1994, Dr. Merskey and Bogduk classified pain according of the International
Association for Study of pain (ISAP) into different groups such as based on: intensity
and time (mild, moderate, and severe; acute and chronic pain), body part involved
(abdominal pain, back pain, pelvic pain, headache), etiology (cancer and noncancerous), and systems whose dysfunction may be causing pain (gastrointestinal,
nervous) [322, 323]. Chronic pelvic pain has long duration and is restricted to the
pelvic area. Mostly genital-tract based problems such as bladder and uterus causes
chronic pelvic pain. One of the most prominent cause of chronic pelvic pain is
IC/PBS [324].
Mast cells (MCs) and the Role of MCs in IC/PBS
MCs are the multifunctional immune cell source from multi-potent
hematopoietic progenitor in the bone marrow, which are produced as undifferentiated
MC and they become mature and acquire their characteristics in the tissues they are
sent [165-169].

MCs produce many potent inflammatory mediators such as

histamine, tryptase, cytokines, and chemokines (especially MCP-1) [325, 326]. MCs
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express high affinity immunoglobulin E receptors (FceR1) [327]. It has found that
these secreted products from MC directly or indirectly have effects on IC/PBS [27,
328-330]. Mast cell amount increased 10 fold in the lamina propria of IC bladder
biopsies [49, 77, 258]. It is still not clear why MC migrates to the bladder and
proliferates in the bladders of IC/PBS patients. One possible explanation is that
damaged urothelium cells secrete cytokines and growth factors that cause migration
of the MCs to the bladder and their activation [49, 325, 331-334]. MC plays roles in
allergic reactions, innate immunity and autoimmunity [123, 165, 166].
Mast cell and Chronic Pelvic Pain of IC/PBS
There is a communication between MCs and neurons through mediators. MCs
can induce neuronal activity by releases of histamine [335, 336]. Mast cells mostly
accumulate at the end of nerve endings in many different tissues, including the
epithelium [335, 337, 338]. Secretions of the activated MCs cause neural sensitization
and more secretion of mast cell activators and it is believed that this vicious cycle
may contribute the pain in IC/PBS [33, 38]. MCs play fundamental role in numerous
pain related diseases such as IC/PBS, IBS, postoperative and neuropathic pain [114,
123, 339, 340]. Other study showed mast cell along with pain is most important sign
of IC/PBS [341, 342]. Those results show that MC have a central role in the IC/PBS
pathogenesis via stimulation of neuronal systems or other unknown mechanism [336].
Histamine and the Role of Histamine in IC/PBS
Histamine is an organic nitrogen compound (Figure 1), a neurotransmitter
[253, 343] and is produced by MCs and neurons [271, 344]. Neurons and MCs have
histamine receptors on their surfaces [274, 276]. Histamine released from MCs play
an important role in local immune responses and physiological functions in tissues
[253]. MCs release histamine which induces degranulation of itself [270]. Histamine
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induces neuronal hypertrophy and mast cell density [269, 271]. Histamine depolarizes
neurons [272] and mediates pelvic pain [273]. Some investigators have shown that
IC/PBS patients have increased levels of urinary histamine metabolites [77, 258, 259].

Figure 1: The chemical structure of Histamine.
Histamine receptors
Histamine receptors were described in previous paragraphs. Previously, four
types of histamine receptors (histamine receptor type 1 to type 4(H1- H4) have been
described [345].
Histamine H1 receptors are dispersed in a broad variety of organs, e.g. central
nervous system [345], smooth muscle, gastrointestinal tract, cardiovascular system,
endothelial cells and lymphocytes [346]. Histamine H2 receptors are found in a
variety of tissues including brain, gastric parietal cells and cardiac tissues [260].
The role of MCP-1 and its receptor CCR2 on MCs and Pain
Monocyte chemoattractant protein MCP-1 (CCL2) is a member of the C-C
chemokine family and may has chemotactic effect on monocyte and MC [347]. MCP1 also itself may plays a role in degranulation of mast cell [348]. MCP-1 suggests as a
biomarker for the CPPS and IC/PBS [349, 350]. MCP-1 and its -chemokine-receptor2 (CCR2) have been shown that they can cause neuronal hyperexcitability after
chronic nerve compression injury [351]. MCP-1 and CCR2 play a role in microglial
activation and neuropathic pain. Administration of MCP-1 to rat causes tactile
allodynia. In the contrast, MCP-1 neutralizing antibody reduced neuropathic pain
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[352]. IC patients exhibited increased levels of MCP-1 in urine, and bladder tissue
and the expression of MCP-1 is correlated with IC [350]. MCP-1 can also be a good
therapeutic biomarker for IC/PBS and CP/CPPS [353].
IC/PBS and CP/CPPS meaningfully overlap with the symptoms of pelvic pain
and other common conditions therefore; MCP-1 can be a therapeutic biomarker for
CP/CPPS and IC/PBS [354].
Referred Visceral Pain
Referred visceral pain is the kind of unpleasant feeling, when internal organs
are damaged or injured [355]. It is one of the most common symptoms caused by
diseases of internal organs; this symptom is one of the most common reasons that
brings patient to the clinic [324, 356]. Referred visceral pain sources from internal
organs (bladder, colon, ovary, uterus liver and so on), but it is perceived from at
different skin locations other than stimulus region [357]. There is a very famous
theory for the mechanism of referred visceral pain; this pain is due to a convergence
of somatic and visceral fiber at the level of spinal cord [355]. There are many studies
showing that referred visceral pain can be measured by von Frey filaments [114, 358360], one of the most popular non-invasive techniques used in urology for
prototyping. This Filament was calibrated at different forces from 0.008g to 300g that
assess pain. Pain measurement location is the place that is signed with red circles
(Figure 2).
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Figure 2: Von Frey Filaments and measurement locations.
Both pictures at top are a von Frey filament forces that use for pain assessment. The
red circle at the bottom left panel shows where we poke for referred visceral
hyperalgesia measurement, and the bottom right panel represents what kind of place
we used for the measurement. It has a chamber with a mesh floor (right top) [273,
361].
Animal Models
We have been lack of animal models of IC/PBS a long time to discover the
pathophysiology of the disease.

That is why, many studies has recently been

proposed to get an animal model. Those are respectively described below.
In 1992, an animal model was reported by induction of bladder inflammation
with syngeneic bladder antigen [362]. BALB/cJ mice were used for that. It was a
bladder specific and cell-mediated autoimmune response model [362].
A transgenic model was designated as URO-OVA and URO-OVA/OT-I mice
[363]. In this model, the bladder epithelium actively produces self-Ag (OVA Ag) to
the immune system. After that the antigen induces CD8 (+) T cell tolerance,
activation, and autoimmune response [363].
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Dr. Christensen et al. were created an animal model in a guinea pig in which
bladder was induced by a protein that had been previously used to the animal resulted
in bladder inflammation [364].
Many researchers used feline interstitial cystitis model. This model is creating
a spontaneous idiopathic cystitis in domestic cats [365-367]. The models
demonstrates urinary urgency, frequency, and pain with sterile urine, bladder
mastocytosis, increased histamine excretion, increased bladder permeability,
decreased urinary GAG excretion [368]. Beside cats, some researcher also used
African monkeys to create a model that mimics the symptoms of IC/PBS by using
acetone intravesically [369]. Many rat models were also created such as rat bladder
induce by hydrochloric acid and bladder induced by virus for neurogenic cystitis
[370].
In 2011, Dr. Oottamasathien et al. used C57B/L6 mice to create a new model
for bladder inflammation by using LL-37 peptide. LL-37 is a urinary defense peptide
works as an antimicrobial [371].
Lastly, our laboratory produced a novel experimental autoimmune cystitis
mouse model that represents all symptoms of human IC except pelvic pain by using
recombinant uroplakin II protein injection [372]. Other model is created by same
group is that this EAC group were immunized with mouse bladder homogenate in
complete Freund's adjuvant (CFA) and a control group immunized with CFA alone
[55, 373].
There are over than 15 interstitial cystitis models have been proposed so far
[374]. Some of them are induced by intravesical irritants and immune substances to
produce

inflammation.

Some

examples
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of

substances

are

those

(e.g.,

cyclophosphamide, hydrochloric acid, protamine sulphate, mustard oil, turpentine,
and lipopolysaccharide) used for induction of Cystitis [374, 375]. Moreover, some of
them were produced genetically. However, most of them were not too specific to
bladder as human IC/PBS itself. In addition, those models can not represent the
human IC/PBS symptoms. Because of that, we still need to have very specific model
for human IC/PBS in animal [374]. Although animal models can yield clues to
etiology, all theories must ultimately be tested in humans with the disease.
Experimental autoimmune cystitis (EAC) mouse model
Our laboratory, in the Department of Urology at Case Western Reserve
University, recently created an experimental autoimmune cystitis (EAC) mouse model
(BALB/cJ) that mimics exactly human IC/PBS patients in term of both immunologic
and urodynamic phenotype. Many animal models have been created by the same
autoimmune mediated targeted techniques used such as autoimmune myocarditis,
autoimmune oophoritis, and autoimmune encephalomyelitis as models of autoimmune
diseases, and then they were used successfully for investigation of diseases [376,
377]. In this model, we showed a chronic pelvic pain phenotype at different times
(early onset and persistence of pain). Moreover, we showed a MC specific marker
(FceRI), and increased MCP-1 transcription level in this model. Those new findings
give us a piece of mind to study the mechanism of chronic pelvic pain in this model
by targeting the role of MCP-1, CCR2 and MCs.
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The Significance

The mechanism of pelvic pain in IC/PBS is unknown. The determination of
the mechanistic role of MCP-1, its receptor CCR2, and MC histamine, in chronic
pelvic pain of experimental autoimmune cystitis (EAC) mouse model, could improve
our understanding of the pathogenesis of IC/PBS for new therapeutic approaches.
This study will give us better understanding of IC/PBS pathophysiology.
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CHAPTER II
II.GENERAL MATERIALS AND METHODS
Mice and immunization
Female BALB/cJ mice were purchased from Jackson Laboratory (Bar Harbor,
ME). Adult female and male MCP-1-deficient (MCP-1-/-) mice [378] and CCR2deficient (CCR2-/-) mice [379] on the BALB/c background were obtained from Dr. B.
Rollins (Harvard Medical School, Boston, MA) [380] and Dr. N. Mukaida (Kanazawa
University, Kanazawa, Ishikawa, Japan) [381]. Knockout mice were bred and all mice
were maintained on a regular 12:12 hour light:dark cycle with ad libitum food and
water in the Animal Resource Center of Case Western Reserve University. At 8-10
weeks of age, mice were injected subcutaneously in the upper abdominal flank with
200 µg of mouse uroplakin 3A 65-84 (UPK3A 65-84) peptide in 200 µl of an
emulsion of equal volumes of water and complete Freund’s adjuvant (CFA)
containing 400 µg of Mycobacteria tuberculosis H37RA (Difco Laboratories, Detroit,
MI), or with CFA and water alone. This maximum concentration of UPK3A 65-84
peptide was chosen based on our previous studies [382]. Mice were euthanized by
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asphyxiation with carbon dioxide followed by cervical dislocation 10, 20, or 40 days
after immunization. All protocols were preapproved by the Institutional Animal Care
and Use Committee of Case Western Reserve University in conformity with the
Public Health Service policy on humane care and use of laboratory animals.
Peptide
Uroplakin 3A 65-84 peptide was used to create EAC mouse model on
BALB/cJ background mice in our laboratory [73, 383]. This peptide was purchased
from Cleveland Clinic at Molecular Biotechnology/ Peptide Synthesis core facility of
Lerner Research Institute. They used standard solid phase methodology and FMOC
side chain-protected amino acids. Peptide was purified >97% by reverse phase HPLC
and amino acid composition was confirmed by mass spectrometry. This peptide
sequence were selected based on immunogenicity on BALB/cJ mice [73].
Pain assessment
Tactile sensitivities of the suprapubic and hindpaw regions of mice, with the
former considered a surrogate for pelvic visceral pain [384], were measured using a
series of 14 von Frey filaments with increasing calibrated forces from 0.008g to 10.0g
(Stoelting Co., Wood Dale, IL). These filaments provide an approximately
logarithmic series of forces and a linear scale of perceived intensity. Beginning with
the smallest filament, each filament was applied a total of 10 times for 3 seconds, with
intervals of 8 seconds between each stimulus. The behaviors that were considered to
be a positive response were: 1) sharp retraction of the abdomen or hindpaw, 2) instant
licking and/or scratching of the stimulated area, or 3) jumping. The results are
expressed as the percentage of positive responses out of 10 trials (response frequency)
for each monofilament. In addition, the von Frey force defined as that which would
elicit a response 50% of the time (50% threshold) was calculated for each mouse from
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the regression line drawn through the linear portion of a plot of response frequency
vs. log of the von Frey force, using GraphPad Prism 5 (GraphPad Software, Inc., La
Jolla, CA).
Lidocaine instillation
On the 40th day after immunization, while the mice were under isofluraneanesthesia, the local anesthetic lidocaine (Sigma-Aldrich; 50 µl of a 2 % solution in
sterile water) was instilled into the bladder, colon, or uterus of UPK3A 65-84immunized mice using a 24 gauge, 0.7×19mm catheter (BD Angiocath™
Autoguard™, BD Medical Systems, Sandy, UT, ref. #381700). Saline was
administered to CFA-injected control mice. Pain assessment was performed using von
Frey filaments one hour after drug administration.
Mast cell staining and counting

Mouse bladders were fixed in 10% phosphate-buffered formalin, embedded in
paraffin, and sectioned using a microtome. For staining of MCs, bladder cross
sections were deparaffinized, hydrated sequentially with xylene, alcohol and dH2O,
and stained in 0.1% toluidine blue working solution for 2-3 minutes. After rinsing
with dH2O and dehydration, slides were mounted with coverslips using Cytoseal XYL
mounting medium solution (Richard-Allan Scientific). Activated and resting MCs
were distinguished under a light microscope at 40x magnification and counted
separately. MCs were counted in eight different toluidine blue-stained sections of the
bladder of each mouse.
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Reverse transcription and quantitative real time PCR (qRT-PCR)

Bladders of UPK3A 65-84-immunized and control mice were harvested 10,
20, and 40 days after immunization and cut in half. One half was frozen and stored at
−80°C for ELISA; the other half was homogenized in TRIzol reagent (Invitrogen,
Carlsbad, CA) and total RNA was isolated. cDNA was synthesized from the RNA
using a Super Script III cDNA synthesis kit with random hexamer primers
(Invitrogen). The cDNAs were analyzed for expression of the genes for MCP-1, Fc
epsilon receptor 1 alpha (FceRI), and β-actin (loading control) by qRT- PCR, using
gene-specific primer pairs designed with the online Universal Probe Library Assay
Design Center (Roche, Mannheim, Germany). The sequences of the primer pairs are:
MCP-1,

CACAGTTGCCGGCTGGAGCAT

GTAGCAGCAGGTGAGTGGGGC

(sense)

(antisense);

and
FceRI,

TGGGGGCTCAGTGCCTGTCA (sense) and CCAAGGCTTCGGGATGCTTGAGG
(antisense);

β-actin,

GGTCATCACTATTGGCAACG

(sense)

and

ACGGATGTCAACGTCACACT (antisense). qRT-PCR was performed using a
SYBR Green PCR Master kit with an ABI Prism 7500 Sequence Detection System
(Applied Biosystems, Foster City, CA). MCP-1 and FceR1 gene expression levels
were normalized to expression of the β-actin gene and calculated relative to the
average level in CFA-immunized mice by the comparative CT method [385].
Treatment with sodium cromolyn
Sodium cromolyn (Sigma Aldrich, St. Luois, MO) is used as a mast cell
stabilizer. Each mouse was treated with sodium cromolyn orally as 10mg/kg by using
a Hamilton syringe with rounded tip needle which is 2.5cm long[386]. The drug was
given 3 times a day with 2-hour intervals. Pain assessment was done using von Frey
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ligament one hour after the last drug administration. The control mice were
administered with saline.
Treatment with a histamine receptor 1 antagonist (cetirizine) and a
histamine receptor 2 antagonist (ranitidine)
Each mouse was treated separately with cetirizine and ranitidine (Sigma
Aldrich, St. Luois, MO) orally as 10mg/kg by using Hamilton syringe with rounded
tip needle which is 2.5cm long [387, 388]. The drug was given 3 times a day with 2hour intervals. Pain assessment was done using von Frey ligament one hour later after
the last drug administration. The control mice were administered with saline.
Treatment of CCR2b antagonist
The CCR2b antagonist RS 102895 [389] (all from Sigma-Aldrich, St. Louis,
MO) is a potent antagonist of MCP-1(CCL2) receptor and a member of the
spiropiperidine. Each mouse was orally administered with 10mg/kg/day starting from
day 1 until day 20 [390]. After 20 days treatment, mice were assessed in term of
pelvic pain with von Frey filament graded from 0.004g to 4g. On the same day after
pain assessment, all mice (Saline given-CFA immunized mice, n=10; CCR2b-treated
UPK 3A immunized mice, n=10; Saline given-UPK 3A immunized mice, n=10) were
scarified to harvest their bladder for mast cell counting by staining of toluidine blue.

MCP-1 and IgE ELISA

From the same mice from which bladders were harvested for qRT-PCR and
ELISA, with half of each bladder stored at −80°C for ELISA, blood was collected,
and serum was separated and stored at −80°C. In addition, six other tissues (uterus,
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ovary, colon, liver, kidney, and lung) were harvested from UPK3A 65-84-immunized
mice 40 days after immunization and stored at −80°C. The tissues were homogenized
with a PowerGen 125 homogenizer (Fisher Scientific, Pittsburgh, PA), and protein
concentrations were determined by the method of Bradford (Bio-Rad Protein Assay,
BioRad Laboratories, Hercules, CA). MCP-1 and IgE antibody concentrations were
measured in the tissues and serum, respectively, using ELISA kits (MCP-1, Ray
Biotech, Inc., Norcross, GA; IgE, BioLegend, Inc., San Diego, CA) according to the
manufacturer’s instructions. Absorbances at 450 nm were read in a Versamax ELISA
microplate reader (Molecular Devices, Sunnyvale, CA).

Statistical Approaches

Comparisons of log transformed 50% pain threshold forces, MC numbers,
MCP-1 and FceR1 mRNA levels, and MCP-1 protein levels between two groups of
mice (e.g., UPK3A 65-84- vs. CFA-immunized mice, drug- vs. saline-treated mice,
and wild type (WT) vs. MCP-1-/- mice) were performed using the unpaired, two-tailed
Student’s t test, with Welch’s correction in cases where the variances were
significantly different. Comparisons of 50% pain threshold forces in immunized mice
at different time points with naïve mice, and MCP-1 protein levels in multiple tissues
with the level in bladder, were performed using one way analysis of variance
(ANOVA) with Dunnett’s multiple comparison test. Comparisons of MC numbers
among wild type and knockout mice immunized with UPK3A 65-84 or CFA were
performed using one way ANOVA with Tukey’s multiple comparison test. Values of
p<0.05 were considered statistically significant.
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CHAPTER III
III.RESULTS
1- Early onset and persistence of pain in EAC mice

We used our previously created model of EAC in female BALB/cJ mice, in
which the bladder-specific UPK3A 65-84 peptide induced a CD4+ T cell-mediated
autoimmune response that mimicked the major symptoms of human IC/PBS,
including elevated urinary frequency, decreased urine output per void, and increased
pelvic pain responses (K. Izgi, et al., submitted). In this study, we evaluated the onset,
duration, and specificity of pain induced by UPK3A 65-84 in comparison to CFAimmunized mice (control) and uninjected naïve mice (baseline). Mechanical
stimulation of UPK3A 65-84-immunized mice on both the suprapubic region (Fig.
3A) and the hindpaw (Fig. 3D) with von Frey filaments of increasing size resulted in
significantly greater pain sensitivity relative to naïve mice within 5 days of
immunization and persisting through day 40, at which time the experiment was
terminated. Much smaller increases in pain sensitivity relative to naïve mice were
observed in CFA-immunized mice stimulated on both the suprapubic region (Fig. 3B)
and the hindpaw (Fig. 3E) 5 to 40 days after immunization. Calculation of 50%
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threshold forces revealed significantly lower pain thresholds in UPK3A 65-84immunized mice stimulated on both the suprapubic region (Fig. 3C) and the hindpaw
(Fig. 3F) relative to CFA-immunized mice at all time points. Comparison of results
from CFA-injected mice at different time points with naïve mice by one way ANOVA
with Dunnett’s multiple comparison test revealed barely significant decreases in 50%
thresholds on the suprapubic region 20 and 30 days after immunization, and
moderately significant decreases in 50% thresholds on the hindpaw 20, 30, and 40
days after immunization.
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Figure 3: Immunization with UPK3A 65-84 peptide causes early and chronic
pelvic pain in female BALB/cJ mice.
Mice were assessed for referred visceral hyperalgesia by applying a series of 14 von
Frey filaments of increasing forces to the suprapubic region (A-C) and hindpaw (DF). Each data point in A, B, D, and E indicates the mean response frequency
(percentage of responses out of 10 trials) plus and minus the standard error of the
mean (SEM) on the indicated number of days after immunization with UPK3A 65-84
(A,D) or CFA (B,E), or in naïve mice (n=10 mice per group). Data points in C and F
indicate the mean 50% threshold forces ± SEM determined by linear regression of
response frequency vs. log of the filament force for the three groups at the indicated
time points. UPK3A 65-84-injected mice had substantially increased pain on both the
suprapubic area (A) and hindpaw (D) compared to naïve mice. Much smaller
increases in pain responses were observed in CFA-injected mice in the suprapubic (B)
and hindpaw regions (E) compared to naïve mice. At every time point, the mean 50%
threshold in mice immunized with UPK3A 65-84 was significantly lower than in
CFA-injected mice on both the suprapubic region (C) and hindpaw (F), as determined
by unpaired t tests of log transformed 50% pain thresholds with Welch’s correction;
levels of significance are indicated on the graphs. Comparisons of log transformed
50% thresholds in immunized mice at different time points with naïve mice by one
way ANOVA with Dunnett’s multiple comparison test revealed significant decreases
in UPK3A 65-84-immunized mice on both the suprapubic and hindpaw regions at all
time points (p<0.001), while CFA-injected mice exhibited barely significant decreases
on the suprapubic region 20 and 30 days after immunization (p<0.05), and moderately
significant decreases in 50% thresholds on the hindpaw 20, 30, and 40 days after
immunization (p<0.01).

2- Chronic pelvic pain in EAC mice emanates from the bladder.
To determine whether the pain in EAC mice emanated from the bladder or not,
lidocaine was instilled directly into the bladder under anesthesia of mice for 60
minutes by using 24GA 0.75 IN 0.7x19mm catheter (BD Angiocath Autoguard, UtahUSA, ref#381700). After waking up, each mouse was assessed in terms of referred
visceral hyperalgesia by using von Frey fibers to show the difference between three
groups: the peptide-immunized mice with lidocaine-treatment, the peptide-immunized
mice with saline-treatment and CFA immunized mice with saline-treatment.
Installation of lidocaine into the bladder significantly reduced pelvic pain in both on
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suprapubic region (Fig. 4A) and on paw region (Fig. 4B). The same procedure for
instillation of lidocaine into colon had no effect on the pelvic pain in both on
suprapubic region (Fig. 4C) and on paw region (Fig. 4D). The same procedure for
instillation of lidocaine into uterus had no effect on the pelvic pain in both on
suprapubic region (Fig. 4E) and on paw region (Fig. 4F).
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Figure 4: Lidocaine reduces pain of UPKA3A 65-84-immunized mice when
instilled into the bladder.
Instillation of lidocaine into the bladders of UPKA3A 65-84-immunized mice resulted
in significantly increased 50% pain thresholds of von Frey filaments applied to the
suprapubic region (A, p=0.0006 by unpaired t test of log transformed 50% pain
thresholds with Welch’s correction) or hindpaw (B, p=0.0004), to levels that were not
significantly different from control mice injected with CFA + saline (n=10 per group).
On the other hand, instillation of lidocaine into the colon or uterus had no effect on
50% pain thresholds on either the suprapubic region (C,E) or hindpaw region (D,F).
Data points indicate the mean response frequencies plus or minus SEM.

3-The EAC mouse model has increased MC in the bladder
We examined MC amount as well as the activation status of MC. There are
two types of MC status: resting and activated MC in the tissues. Activated MC are
granulated (more intense staining) and resting MC have a few or no granules in the
cell boundary, when the bladder is stained with toluidine blue (Figure 5A). Figure 5B
showed a representative staining of bladder of immunized mice with CFA control
mice versus UPK3A 65-84 immunized mice. We can easily say that there is a
significant accumulation of MC in the peptide-immunized mouse (Figure 5B). The
number of total MC significantly increased in UPK3A 65-84 peptide immunized mice
compared to CFA-immunized mice alone at different time points by staining with
toluidine blue (Figure 5E). The number of activated mast cells was more than the
number of resting MCs. Both of them significantly increased in the peptideimmunized mice compared with CFA-immunized mice alone on 10th, 20th, and 40th
days (Figure 5C, D). We also showed that FceRI gene expression significantly
increased on 10th, 20th, and 40th days in immunized mice compared control group
(Figure 5F).
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Figure 5: Increased MC accumulation in bladders of mice immunized with
UPK3A 65-84 peptide.
MCs in bladder cross sections from UPK3A 65-84- and CFA-immunized mice were
stained with toluidine blue (A), then activated MCs with less visible cytoplasmic
granules and resting MCs with more granules (all cytoplasm is stained due to
invention of granules) were counted separately under a light microscope at 40x
magnification (B, MCs are indicated by arrows). MCs were counted in eight different
sections of each bladder. At 10, 20, and 40 days after immunization, bladders from
UPK3A 65-84-immunized mice contained significantly more activated (C), resting
(D), and total (E) MCs compared with CFA-injected mice (n=10 mice per group at
each time point). Also, FceRI gene expression was significantly increased in UPK3A
65-84-immunized relative to CFA-injected mice 10, 20, and 40 days after
immunization (n=8 mice per group-time point) (F). Each column indicates the mean
plus standard deviation (SD); p values indicated on the graphs are results of unpaired t
tests, all with Welch’s correction.

4-The administration of ranitidine, cetirizine and cromolyn sodium
attenuated chronic pelvic pain in EAC model
Many drugs such as cetirizine, ranitidine and cromolyn sodium stop MC
related effects such as pain. That is why we used this drug to show the role of MC in
pelvic pain. The MC stabilizer, Cromolyn sodium, significantly reduced pelvic pain in
both on suprapubic region (Figure 6A) and on paw region (Figure 6D) by giving the
drug 3 times a day with 2 hours interval. The antihistamine specific H1 receptor
blocker, Cetirizine, reduced pelvic pain in both on suprapubic region (Figure 6B) and
on paw region (Figure 6E) by giving the drug 3 times a day with 2 hours interval.
Furthermore, the antihistamine specific H2 receptor blocker (Ranitidine) significantly
reduced pelvic pain in both on suprapubic region (Figure 6C) and on paw region
(Figure 6F) using the same protocol. Pain was measured for each trial after one hour
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by the end of last dosage administration (10 mg/kg). Finally, Those results show that
mast cell products especially histamine has very important role in the pelvic pain.
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Figure 6: MC stabilizer and antihistamines reduce pain in UPK3A 65-84immunized mice.
Oral administration of the MC stabilizer cromolyn sodium to UPK3A 65-84immunized mice resulted in significantly higher 50% pain thresholds with von Frey
filaments applied to both the suprapubic region (A, p=0.0004) and hindpaw (D,
p=0.0014), to levels that were not significantly different from control mice injected
with CFA + saline. Antagonists of histamine receptors 1 (cetirizine) and 2 (ranitidine)
significantly reduced pain (increased 50% thresholds) of von Frey filaments applied
to the suprapubic region (B, cetirizine, p=0.0025, and C, ranitidine, p=0.0025
compared to saline vehicle-treated, UPK3A 65-84-immunized mice). However, while
ranitidine reduced hindpaw pain responses significantly (F, p=0.0072), cetirizine did
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1

von Frey filament (g)
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not (E). Of the two histamine receptor blockers, only ranitidine reduced pain to levels
that were not significantly different from CFA + saline control mice, on both the
suprapubic (C) and paw regions (F). Drugs were administered and pain assessment
was performed as described in Materials and Methods. n=10 mice per group; p values
are results of unpaired t-tests of log transformed 50% pain thresholds, with Welch’s
correction in cases of significantly different variances. Data points indicate the mean
response frequencies plus or minus SEM.

5- MCP-1 level specifically increased in bladder of EAC mice that have
the same amount of IgE compared with CFA-Control group.
MCP-1 levels were quantified both transcription level and translational level
in bladder of EAC mice. Bladders of both control (CFA) and immunized mice were
harvested, and bladders were cut in the middle of it. One-half was kept for RT-PCR,
and other-half was kept for ELISA. MCP-1- mRNA and protein level in UPK 3A 6584 immunized mice is significantly higher than CFA immunized mice alone at 10th,
20th, 40th day (Figure 7A, B). MCP-1 specifically increased in bladder of EAC mice
other than the organs showed in the graph (Figure 7C). IgE level of EAC mice in
serums is almost same with Control –CFA immunized group (Figure 7D). To sum up,
these outstanding results demonstrate that MCP-1 level is consistently elevated in
bladder of EAC mice. It also correlates with MC accumulation in terms of time points
(Figure 5).
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Figure 7: Immunization with UPK3A 65-84 peptide induces MCP-1 production
in the bladder. There is no significant difference amount of IgE between peptide
immunized mice and CFA immunized mice.
UPK3A 65-84-immunized and CFA control mice were sacrificed and bladder and
other organs were harvested and processed 10, 20, and 40 days after immunization.
MCP-1 mRNA (A) and protein (B) levels quantified by reverse transcription/qRTPCR and ELISA, respectively, were significantly higher in UPK3A 65-84-immunized
mice at all three time points. §n=8 per group, p=0.005; †n=8 per group, p<0.0001;
‡
n=5 per group, p =0.013; and *n=10 per group, p<0.0001 by unpaired t tests, using
Welch’s correction for all except MCP-1 gene expression at 20 days. C. The level of
MCP-1 protein was substantially higher in the bladder compared to six other organs in
EAC mice 40 days after immunization with UPK3A 65-84 peptide (n=3 per group,
p<0.001 comparing each organ to bladder by one way ANOVA with Dunnett’s
multiple comparison test). D. There is no difference amount of IgE in serum of
immunized and control mice by using two sample t-test. Each column indicates the
mean plus SD.

6-MCP-1 -/- mice decreased suprapubic pelvic pain.
MCP-1 -/- mice was obtained as a gift from Dr. Barrett Rollins (Harvard
Medical School, Boston, MA). Autoimmunity against UP3A 65-84 peptide causes
chronic cystitis in WT BALB/cJ mice resulting in chronic pelvic pain (figure 8B).
However, immunization MCP-1-/- BALB/cJ mice (Figure 8A) were not showed any
pelvic pain development at time courses versus WT peptide immunized mice (Figure
8B). Peptide immunized MCP-1 -/- mice (Figure 8A) have the same pain responses
with WT CFA immunized control group (Figure 8D) which also showed MCP-1 is
again very important in pelvic pain development. Mechanical stimulation of
suprapubic area by the filaments resulted in non-significant increment between CFA
immunized mice groups compared to baseline mice (without any injection) on the
suprapubic region (Figure 8D) during the 40 days of the experiment. In contrast, there
was a significant difference between naive (baseline) mice and peptide-immunized
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mice in terms of pelvic pain percentage response at all fibers on suprapubic region
(Figure 8B). There was no any significant difference between naive (baseline) mice
and peptide-immunized MCP-1 -/- mice in terms of pelvic pain percentage response at
all fibers on suprapubic region (Figure 8A) during the 40 days of the experiment. 50%
threshold of immunized mice is significantly decreased compared MCP-1 -/- mice due
to being more sensitive to the pain (Figure 8C). However, 50% threshold of CFA
mice is significantly almost same compared MCP-1 -/- except 40 day due to WT mice
can be more sensitive than the immunized KO mice (Figure 8F). Those data showed
that MCP-1 plays very important role in chronic pelvic pain development of EAC
mice model. Based on these studies, we can use MCP-1 as a target in term of further
investigation and therapeutic approaches of IC/PBS patients.
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Figure 8: MCP-1-/- mice exhibit significantly less suprapubic pelvic pain
compared with wild type (WT) BALB/cJ mice after immunization with UPK3A
65-84.
Mice were assessed for referred visceral hyperalgesia 5, 10, 20, 30, and 40 days after
immunization by applying von Frey filaments of increasing forces to the suprapubic
region as described in Materials and Methods. Mean response frequencies ± SEM
were plotted against the log of the von Frey force (A, WT naïve and UPK3A 65-84immunized mice; B, MCP-1-/- naïve and UPK3A 65-84-immunized mice; D, WT
naïve and CFA-immunized mice; E, MCP-1-/- naïve and CFA-immunized mice; n=10
mice per group). In addition, 50% thresholds were calculated as described in
Materials and Methods; data points in graphs C and F indicate the mean 50%
thresholds ± SEM at the indicated time points. UPK3A 65-84 immunization yielded
significantly less suprapubic pain in MCP-1-/- mice than it did in WT mice at all time
points (C; p values on the graph are results of unpaired t tests of log transformed 50%
pain thresholds with Welch’s correction). CFA (control) immunization yielded
significantly less suprapubic pain in MCP-1-/- mice than it did in WT mice 40 days
after immunization, but not at any other time point (F; p value on the graph is the
result of an unpaired t test). Furthermore, 50% thresholds were not significantly
different in MCP-1-/- mice injected with UPK3A 65-84 compared with MCP-1-/- mice
injected with CFA at any time point (compare red lines in C and F).

7-MCP-1 -/- mice decreased paw pain
MCP-1 -/- mice was obtained as a gift from Dr. Barrett Rollins (Harvard
Medical School, Boston, MA). Autoimmunity against UP3A 65-84 peptide causes
chronic cystitis in WT BALB/cJ mice resulting in pain of paw region (Figure 9A).
However, immunization MCP-1 -/- BALB/cJ mice (Figure 9B) were not showed any
paw pain development at time courses versus WT peptide immunized mice (Figure
9A). Peptide immunized MCP-1 -/- mice (Figure 9B) have the same pain responses
with WT CFA immunized control group (Figure 9D) which also showed MCP-1 is
again very important in pelvic pain development. Mechanical stimulation of paw area
by the filaments resulted in non-significant increment between CFA immunized mice
groups compared to baseline mice (without any injection) on the paw region (Figure
9D) during the 40 days of the experiment. In contrast, there was a difference between
naive (baseline) mice and peptide-immunized mice in terms of percentage of paw pain
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response at all fibers on paw region (Figure 9A). There was no any significant
difference between naive (baseline) mice and peptide-immunized MCP-1 -/- mice in
terms of percentage of paw pain response at all fibers on paw region (Figure 9B)
during the 40 days of the experiment. 50% threshold of immunized mice is
significantly decreased compared MCP-1 -/- mice due to being more sensitive to the
pain (Figure 9C). However, 50% threshold of CFA mice is almost same compared
immunized MCP-1 -/- (Figure 9F). Those data showed that MCP-1 plays a crucial
role in paw area related pain development of EAC mice model. Based on these
studies, we can use MCP-1 as a target in term of further investigation of pain.
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Figure 9: MCP-1-/- mice exhibit significantly less hindpaw pain compared with
WT BALB/cJ mice after immunization with UPK3A 65-84.
The mice used to generate the data for Figure 8 were also assessed for referred
visceral hyperalgesia by applying von Frey filaments to the hindpaw. Mean response
frequencies ± SEM was plotted (A, B, D, and E) and mean 50% thresholds ± SEM
were calculated and plotted (C, F) as in Figure 8. UPK3A 65-84 immunization
yielded significantly less hindpaw pain in MCP-1-/- mice than it did in WT mice at all
time points (C; p values on the graph are results of unpaired t tests of log transformed
50% pain thresholds with Welch’s correction). Hindpaw pain responses were not
significantly different in CFA-immunized MCP-1-/- mice compared to CFAimmunized WT mice at any time point (F). Furthermore, 50% thresholds were not
significantly different in MCP-1-/- mice injected with UPK3A 65-84 compared with
MCP-1-/- mice injected with CFA at any time point (compare red lines in C and F).

8- MCP-1 is required for MC accumulation and activation in bladder in response to
UPK 3A 65-84 immunization.

MCP-1 is a member of chemokine family. The aim is to show whether the
MCP-1 is effective to decrease MCs accumulation. MCP-1 -/- mice was obtained as a
gift from Dr. Barrett Rollins (Harvard Medical School, Boston, MA). After all
groups’ immunization, all mice (CFA injected WT mice, n=10; UPK 3A 65-84
injected WT mice, n=10; UPK 3A 65-84 injected MCP-1 KO mice, n=10; CFA
injected MCP-1 KO mice, n=10) were scarified to harvest their bladder for mast cell
counting after staining with toluidine blue. The results showed that total mast cell
decreased in MCP-1 -/- mice bladder compared to peptide immunized WT mice. The
same correlation also occurred in resting and activated mast cell accumulation. All
results are significantly different (*p<0.001).
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Figure 10: MC accumulation and activation in the bladder in response to
immunization is markedly attenuated in MCP-1-/- mice.
On the 40th day after immunization, all mice in which pain was assessed for Figures
8,9 were sacrificed one hour after pain assessment, then bladders were harvested and
processed for toluidine blue staining of MCs as described in Materials and Methods.
Activated and resting MCs were counted in bladder cross sections from UPK3A 6584- and CFA-immunized WT and MCP-1-/- mice (n=10 mice per group). Numbers of
activated, resting, and total MCs were significantly higher in bladders from UPK3A
65-84-immunized WT mice compared to MCP-1-/- mice immunized with either
UPK3A 65-84 or CFA and to CFA-immunized WT mice (A; *p<0.001 by one way
ANOVA with Tukey’s post test comparing UPK3A 65-84-immunized WT mice with
every other group; no other pairs of groups differed significantly from each other).
Each column indicates the mean plus SD.
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9-CCR2b antagonist decreases pelvic pain
CCR2 is a receptor of MCP-1. This antagonist property on the receptor was
shown in rodents [390]. The aim is to show whether the CCR2b antagonist is effective
to stop MC accumulation and pelvic pain. CCR2b antagonist (RS 102895) was
purchased from Sigma (St Louis, MO. RS 102895) which is a potent antagonist of
MCP-1 (CCL2) receptor and a member of the spiropiperidine. Each mouse was orally
administered RS 102895 10mg/kg/day starting from day 1 until day 20. [390]. After
20 days treatment, mice were assessed in term of pelvic pain with von Frey filament
graded from 0.008g to 4g. The results showed decreased pelvic pain in the peptideimmunized mice that were administered with this compound compared to the peptideimmunized mice and CFA-immunized mice that were not administered with this
compound. The pelvic pain decreased in both on suprapubic region (Figure 11A) and
on paw region (Figure 11B).

After 20 days all mice (CFA alone immunized mice,

n=10; Treated UPK 3A immunized mice, n=10; Untreated UPK 3A immunized mice,
n=10) were sacrificed to harvest their bladder for mast cell counting by staining of
toluidine blue. The results showed that total mast cell decreased in CCR2b antagonisttreated mice compared to other two control groups and number of activated mast cell
is more than the number of resting mast cell (Figure 11C).
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Figure 11: CCR2b antagonist decreases pain and has less mast cell accumulation
in bladder of UPK3A 65-84-immunized mice.
Oral administration of the CCR2b antagonist RS 102895 to UPK3A 65-84immunized mice resulted in significantly higher 50% pain thresholds with von Frey
filaments applied to the hindpaw (B) (p=0.027 by unpaired t test of log transformed
50% thresholds using Welch’s correction), but not to the suprapubic region (A),
compared with saline-treated UPK3A 65-84-immunized mice (n=10 mice per group).
Data points in A and B indicate the mean response frequencies plus or minus SEM.
On the same day after pain assessment, all mice were sacrificed, bladders were
harvested and processed, and MCs were stained with toluidine blue and counted as
described in Materials and Methods (C). The results showed significant decreases in
activated (*p=0.014), resting (§p =0.0002), and total (‡p=0.003) MCs in CCR2b
antagonist-treated compared to saline-treated UPK3A-immunized mice, by unpaired t
tests with (activated, total) or without (resting) Welch’s correction. The decrease in
resting MCs was to a level not significantly different from saline-treated CFA control
mice. Each column indicates the mean plus SD.
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10-CCR2 -/- mice decreased suprapubic pelvic pain.
CCR2 -/- mice were obtained as a gift from Dr. Naofumi Mukaida Cancer
Research Institute, Kanazawa University (Kanazawa, Japan). Autoimmunity against
UP3A 65-84 peptide causes chronic cystitis in WT BALB/cJ mice resulting in chronic
pelvic pain (Figure 12A). In contrast, immunization CCR2-/- BALB/cJ mice (Figure
12B) were not showed any pelvic pain development at time courses versus WT
peptide immunized mice (Figure 12A). Peptide immunized CCR2 -/- mice (Figure
12B) have the same pain responses with WT CFA immunized control group (Figure
12D) which also showed CCR2 -/- mice is again very important in pelvic pain
development. Mechanical stimulation of suprapubic area by the filaments resulted in
non-significant increment between CFA immunized mice groups compared to
baseline mice (without any injection) on the suprapubic region (Figure 12D) during
the 40 days of the experiment. In contrast, there was a significant difference between
naive (baseline) mice and peptide-immunized mice in terms of pelvic pain percentage
response at all fibers on suprapubic region (Figure 12A). There was no significant
difference between naive (baseline) mice and peptide-immunized CCR2 -/- mice in
terms of pelvic pain percentage response at all fibers on suprapubic region (Figure
12B) during the 40 days of the experiment. 50% threshold of immunized mice is
significantly decreased compared CCR2 -/- mice due to being more sensitive to the
pain (Figure 12C). However, 50% threshold of CFA mice is almost same compared
immunized CCR2 -/- (Figure 12F). Those data showed that CCR2 plays very
important role in chronic pelvic pain development of EAC mice model. Based on
these studies, we can use CCR2 as a target in term of further investigation and
therapeutic approaches of IC/PBS patients.
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Figure 12: CCR2-/- mice exhibit significantly less suprapubic pelvic pain
compared with WT BALB/cJ mice after immunization with UPK3A 65-84.
Mice were assessed for referred visceral hyperalgesia 5, 10, 20, 30, and 40 days after
immunization by applying von Frey filaments of increasing forces to the suprapubic
region as described in Materials and Methods. Mean response frequencies ± SEM
were plotted against the log of the von Frey force (A, WT naïve and UPK3A 65-84immunized mice; B, CCR2-/- naïve and UPK3A 65-84-immunized mice; D, WT naïve
and CFA-immunized mice; E, CCR2-/- naïve and CFA-immunized mice; n=10 mice
per group). In addition, 50% thresholds were calculated as described in Materials and
Methods; data points in graphs C and F indicate the mean 50% thresholds ± SEM at
the indicated time points. The reductions in suprapubic pain responses in CCR2-/mice compared with WT mice after immunization with UPK3A 65-84 were highly
significant at all time points (C; *p<0.0001 by unpaired t tests of log transformed 50%
pain thresholds). CCR2-/- mice immunized with CFA exhibited significantly less
suprapubic pain than WT CFA-injected mice 5, 10, and 20 days after immunization
(F; *p<0.0001 and §p=0.017 by unpaired t tests; ‡p=0.031 by unpaired t test with
Welch’s correction). Furthermore, 50% thresholds were not significantly different in
CCR2-/- mice injected with UPK3A 65-84 compared with CCR2-/- mice injected with
CFA at any time point (compare red lines in C and F).

11-CCR2 -/- mice decreased paw pain
CCR2 -/- mice were obtained as a gift from Dr. Naofumi Mukaida Cancer
Research Institute, Kanazawa University (Kanazawa, Japan). Autoimmunity against
UP3A 65-84 peptide causes chronic cystitis in WT BALB/cJ mice resulting in pain of
paw region (Figure 13B). However, immunization CCR2-/- BALB/cJ mice (Figure
13A) were not showed any paw pain development at time courses versus WT peptide
immunized mice (Figure 13B). Peptide immunized CCR2 -/- mice (Figure 13A) have
the same pain responses with WT CFA immunized control group (Figure 13D) which
also showed CCR2 -/- mice is again very important in pelvic pain development.
Mechanical stimulation of paw area by the filaments resulted in non-significant
increment between CFA immunized mice groups compared to baseline mice (without
any injection) on the paw region (Figure 13D) during the 40 days of the experiment.
In contrast, there was a difference between naive (baseline) mice and peptide-
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immunized mice in terms of paw pain percentage response at all fibers on paw region
(Figure 13B). There was no significant difference between naive (baseline) mice and
peptide-immunized CCR2 -/- mice in terms of paw pain percentage response at all
fibers on paw region (Figure 13A) during the 40 days of the experiment. 50%
threshold of immunized mice is significantly decreased compared immunized CCR2
-/- mice due to being more sensitive to the pain (Figure 13C). However, 50%
threshold of CFA mice is almost same compared CCR2 -/- (Figure 13F). Those data
showed that CCR2 plays important role in paw area related pain development of EAC
mice model. Based on these studies, we can use CCR2 as a target in term of further
investigation of pain.
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Figure 13: CCR2-/- mice exhibit significantly less hindpaw pain compared with
WT BALB/cJ mice after immunization with UPK3A 65-84.
The mice used to generate the data for Figure 12 were also assessed for referred
visceral hyperalgesia by applying von Frey filaments to the hindpaw. Mean response
frequencies ± SEM were plotted (A, B, D, E) and mean 50% thresholds ± SEM were
calculated and plotted (C, F) as in Figure 12. UPK3A 65-84 immunization yielded
significantly less hindpaw pain in CCR2 -/- mice than it did in WT mice at all time
points (C; *p<0.0001 by unpaired t tests of log transformed 50% pain thresholds).
CCR2-/- mice immunized with CFA exhibited significantly less hindpaw pain than
WT CFA-injected mice 5 and 20 days after immunization (F; *p<0.0001 and
§
p=0.003 by unpaired t tests). 50% thresholds in CCR2-/- mice injected with UPK3A
65-84 were significantly lower than in CCR2-/- mice injected with CFA 20 days after
immunization (p=0.006 by unpaired t test), but not at any other time point (compare
red lines in C and F).

12-CCR2 receptor plays very important role in MCs accumulation in
balder that leads pelvic pain.
CCR2 is a receptor for MCP-1. The aim is to show whether the CCR2
involves in MC accumulation. CCR2 -/- mice were obtained as a gift from Dr.
Naofumi Mukaida Cancer Research Institute, Kanazawa University (Kanazawa,
Japan). After all groups’ immunization, all mice (CFA injected WT mice, n=10; UPK
3A 65-84 injected WT mice, n=10; UPK 3A 65-84 injected CCR2 KO mice, n=10;
CFA injected CCR2 KO mice, n=10) were scarified to harvest their bladder for mast
cell counting by staining of toluidine blue. The results showed that total mast cell
decreased in CCR2 -/- mice bladder compared to peptide immunized WT mice. The
same correlation also occurred in resting and activated mast cell accumulation. All
results are significantly different (*p<0.001, §p<0.01 ).

67

B

60

WT CFA
WT UPK3A

Number of cells

50

CCR2
40

*

CCR2

-/-/-

*

CFA
UPK3A

30
20

*
§

10
0

Activated

Resting

Total

Mast cell component

Figure 14: MC accumulation and activation in the bladder in response to
immunization is markedly attenuated in CCR2-/- mice.
On the 40th day after immunization, all mice in which pain was assessed for Figures
12,13 were sacrificed one hour after pain assessment, then bladders were harvested
and processed for toluidine blue staining of MCs as described in Materials and
Methods. Activated and resting MCs were counted in bladder cross sections from
UPK3A 65-84- and CFA-immunized WT and CCR2-/- mice (n=10 mice per group).
Numbers of activated, resting, and total MCs were significantly higher in bladders
from UPK3A 65-84-immunized WT mice compared to CCR2-/- mice immunized with
either UPK3A 65-84 or CFA and to CFA-immunized WT mice (A; *p<0.001 by one
way ANOVA with Tukey’s post test comparing UPK3A 65-84-immunized WT mice
with every other group; no other pairs of groups differed significantly from each
other). except a significant increase in number of resting mast cells was also found in
UPK3A 65-84-immunized vs. CFA-immunized CCR2-/- mice (§p<0.01 by Tukey’s
post test comparison). Each column indicates the mean plus SD.
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CHAPTER IV
IV.DISCUSSION

In the United States, it is estimated that approximately 1.2 million women and
82,000 men suffering from IC/PBS and the economic burden of IC/PBS patients in
the US was nearly $65.9 million in 2000[8]. The etiology of interstitial cystitis disease
has not been revealed yet[25]. The major symptoms of IC/PBS are urinary frequency,
urgency and pelvic pain[391]. Pelvic pain is the most common symptom of IC/PBS,
and also the most annoying reason that brings the patients to the physician[324].
Numerous animal models have been developed to investigate the pathogenesis of
IC/PBS. The mouse model, which is generated by bladder specific Uroplakin derived
UPK3A 65-84 peptide induced experimentally autoimmune mediated cystitis,
presents the all three major phenotypical characteristic of IC/PBS seen in patients in
terms of urodynamic alterations and particularly pelvic pain. UPK3A 65-84 induced
EAC model is very potent in terms of bladder specific inflammation among the other
created mouse models.
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The various studies have been projected that there could be a relation and
correlation between mast cell and chronic pelvic pain in some diseases such as IBS,
IC, and prostatitis [273, 392].
It has found that secreted products from MCs directly or indirectly have
effects on IC/PBS [328, 329]. Secretions of the activated MCs cause neural
sensitization and more secretion of mast cell activators and it is believed that this
vicious cycle may contribute the pain in IC/PBS [33, 38].It is still not clear why MCs
migrates to the bladder and proliferates in the bladders of IC/PBS patients. One
possible explanation is that damaged urothelium cells secrete cytokines and growth
factors that cause migration of the MCs to the bladder and own activation [49, 325,
331-334].
Moreover, it was also shown that MCs have a pivotal role in the IC/PBS
pathogenesis via stimulation of neuronal systems or other unknown mechanism [336].
It was demonstrated that there is a communication between MCs and neurons through
mediators [335, 393]. Mast cells mostly accumulate at the end of nerve endings in
many different tissues, including the epithelium [335, 337, 338]. Neurons and MCs
have histamine receptors on their surfaces [274, 276]. MCs can induce neuronal
activity by releases of histamine [335]. MC

releases histamine which induces

degranulation of itself [270]. Histamine depolarizes neurons [272] and mediates
pelvic pain [273]. CGRP (calcitonin gene-related peptide), substance P released from
neurons can activate MCs [335, 336].
Furthermore, a study revealed that IC patients exhibited increased levels of
MCP-1 chemokine in urine, and bladder tissue and the expression of MCP-1 was
correlated with IC[350]. MCP-1 has been suggested as a biomarker for the CPPS and
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IC/PBS [349, 350]. The effect of MCP-1 and its -chemokine-receptor-2(CCR2) on
causing neuronal hyperexcitability after chronic nerve compression injury was shown
[351]. MCP-1 itself plays a role in degranulation of mast cell[348]. The roles of the
MCP-1 and CCR2 in microglial activation and neuropathic pain have been shown
[394]. In another study, the administration of MCP-1 to rat induced tactile allodynia,
in the contrast, MCP-1 neutralizing antibody reduced neuropathic pain[352].
Our first report is to show the model develop chronic pelvic pain sourced from
bladder. Secondly, we showed MC accumulates in bladder. Even though some
investigator showed mast cell product such as histamine increased in human
IC/PBS[327] and expression of monocyte chemoattractant protein (MCP-1) was
increased in IC/PBS patients[350], but MC was not showed in transcription and tissue
level.
In our study, we showed that UPK3A 65-84 peptide induced EAC mouse
model develops chronic pelvic pain at different time points. The localization,
modulation and regulation of pelvic pain are characterized in this cystitis model. We
showed this chronic pelvic pain development in detail, because in our first study,
pelvic pain has not been systematically characterized in EAC model[395]. Pelvic pain
in this model remains continual that closely mimic pelvic pain of IC/PBS seen in
human. The pain that reflected on suprapubic region sourced from bladder is proofed
by lidocain installation. The pelvic pain was pharmacologically decreased by
histamine related blockers; ranitidine, cetirizine and cromolyn sodium. In addition to
that, mast cell related blockers showed that the pain in this cystitis mouse model is
due to mast cell accumulation and its secretions.
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We pharmacologically, genetically and at immunostaining level showed that
MCP-1 mediated Mast cell accumulates in bladder that correlate exactly with pelvic
pain at different time points. MCP -1’s translational and transcription level and the
amount of mast cells in bladder significantly increased from 5 days after the peptide
induction to 40 days in BALB/c mice.
We also investigated the role of CCR2, which is also called MCP-1 receptor,
in pathogenesis of chronic pelvic pain of EAC. The first step is that we used CCR2
(MCP-1 receptor) antagonist that significantly decreased pelvic pain and MC
accumulation into bladder by time points. Chemokine (C-C motif) receptor 2 [CCR2],
a well-known MCP-1 receptor, is located on the surface of MCs and has a role in
migration of MC [203].
The best way to understand the role of MCP-1 and its receptor (CCR2) in this
EAC model is to use their knockout in same strain-BALB/cJ. The result of knockout
studies showed that the peptide immunized MCP-1 and CCR2 KO mouse did not
develop the pelvic pain and also has almost same or less amount of MC counts in
bladder compared to CFA-control immunized WT BALB/c mice. It seems that MCP1 and CCR2 has a pivotal role in development of cystitis and chronic pelvic pain.
We report MCP-1 and its receptor (CCR2) mediated MCs have a central role
in pathogenesis of chronic pelvic pain of EAC as a model of IC/PBS. The increase of
MCP-1 in the bladder of EAC model is the most important factor that causes
accumulation MCs in the bladder. While the immune response have obviously crucial
role, the MC and MCP-1 and its receptor (CCR2) might have an essential
consequences for the development and progression of pain symptoms in EAC under
the light of our findings.
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CONCLUSION

MCP-1 mediates chronic pelvic pain through mast cell accumulation in
bladder of EAC mouse model. Our findings on this model will contribute a lot of
beneficial aspects to unknown IC/PBS etiology and pathogenesis. With these new
discoveries for the disease, we can say that MC and MCP-1 is going to be good
candidate in term of therapeutical approaches for pelvic pain treatment clinical trials
and also they can be investigate in any other disease related with pain.

Figure 15: We confirmed all specific aims by the experiments in the figure that
shown above. EAC mice developed chronic pelvic pain (1). Mast cell accumulations
are increased in bladder of EAC mice (2). Finally, it has been shown that MCP-1
plays a role in chronic pelvic pain of EAC through Mast cells (3).
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FUTURE DIRECTIONS

We are going to have further discoveries in our next studies under the light of
our new findings with such a wonderful mouse model. We are planning to use this
model for immunotherapy of bladder cancer by immunization methods. Gene therapy
can be applied in bladder cancer to use MCP-1 gene as a target. New treatment
methods can be pharmacologically created in this disease to target MCs, MCP-1, and
CCR2.
In bladder cancer, a couple of studies showed that Bacillus Calmette–Guérin
(BCG) can be used for immunotherapy of bladder cancer to trigger the inflammation
in bladder [396, 397]. In our case, we can increase inflammation in bladder of mice by
UPK 3a 65-84 peptide while mouse has bladder cancer. This type of method used in
many type of cancer such as prostate, breast, ovarian cancers and other tumors [398,
399]. Other method is a gene therapy that would be constructed plasmid that contain
MCP-1 gene. We will install this plasmid into bladder to trigger inflammation while
the bladder has cancer. Accumulated white based blood cell will attack the cancer
cell to struggle with condition in better bay. For example, in prostate cancer, prostatespecific antigen (PSA), prostatic acid phosphatase (PAP), and prostate-specific
membrane antigen were used as a target to produce a new vaccine for the disease
[400, 401]. One of them is Sipuleucel-T [402, 403]. This drug is in clinical phase trial
III and an immunotherapeutic cellular product, which includes autologous dendritic
cells pulsed ex vivo with a recombinant fusion protein (PA2024) consisting of
granulocyte macrophage colony-stimulating factor and PAP. While applying the drug
in prostate cancer patients, T cell will be activated to attach the prostate cancer cell
which is expressed PAP [403].One study showed that, monocyte chemoattractant
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protein-1 (MCP-1) can play a role in monocyte/macrophage infiltration and enhance
their phagocytosis in cervical cancers. With this perspective, we can target MCP-1 as
gene therapy for bladder cancer [404].
In addition of that, MCs, MCP-1 and CCR2 can be good candidates in term of
new drug discovery for IC/PBS patients. We can pharmacologically design new
compound that block the effects of those targets in term of IC/PBS treatment.
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